Latest news on COVID 19 and PID
IPOPI is committed to monitor closely the COVID-19 pandemic and to share evidence-based and expert validated information to the global primary immunodeficiency (PID) patients community and to our stakeholders.
The situation is evolving rapidly all over the world with new restrictions being imposed in an increasing number of countries. Our priority is the safety of all PID patients and the safety of supply of their life-saving treatments both during and after the COVID-19 pandemic. IPOPI has been engaging on several fronts to fast track the publication of statements, answer frequently asked questions and participate in international efforts to collect data on COVID-19 in PIDs.
This page aggregates all of IPOPI’s efforts and selected external statements.
IPOPI commits to publish and update its statements as the situation evolves. Please always refer to the latest statement which contains up to date recommendations.
27 November, Joint statement, 4th Update:
The forth update of the Joint Statement offers a general update, the latest on treatments as well as new information on COVID-19 in PID patients.
28 May, Joint statement, 3rd Update:
The third update of the Joint Statement, includes a general update, details on paediatric inflammatory multisystem syndrome, COVID-19 tests and more.
08 April, Joint statement, 2nd Update:
The second update of the Joint Statement, now also in partnership with IUIS, includes a general update, new details on treatments, clinical trials of prospect medicines and ongoing medical surveys. Specific precautions for daily life, such as school life and mask wearing also featured.
11 March, Joint statement, 1st Update:
IPOPI published a Joint Statement together with ESID, INGID, APSID, ARAPID, ASID, CIS, LASID and SEAPID on the COVID-19 epidemics.
The Statement covers general and PID specific precautions and advises monitoring of the regional public advices.
Read the Joint Statement:
- 12 February, IPOPI Statement
IPOPI Policy Actions
IPOPI letter to the APEC Blood Policy Forum
IPOPI sent a letter to the APEC Bloof and Policy Forum representatives highlighting the importance of ensuring blood/plasma/PDMP supply during current COVID-19
IPOPI calls on authorities to ensure appropriate supply of immunoglobulins IPOPI just published an Open Letter calling international, regional and national authorities to ensuring sufficient blood and plasma supply during and after the COVID-19 outbreak.
APLUS Letter on Masks Provision to Source Plasma and Blood Collection Facilities to Ensure Supply of Life-Saving Treatments
Open letter from PLUS to EU Ministers of Health
PLUS Statement on Access to Plasma Derived Medicinal Products & home care during the COVID-19 pandemic
COVID-19 Learning Expedition Report released
IPOPI launched the COVID-19 Learning Expedition (LEX) in July 2020, to identify, analyse and provide recommendations on issues brought about by the COVID-19 pandemic for patients with primary immunodeficiency (PID).
Report available here:
Global Survey on COVID-19 and PIDs (for physicians)
IPOPI is participating in the launch of a global survey on COVID-19 and PIDs, working jointly with International Union of Immunological Societies (IUIS) and other medical societies.
The survey is now entering phase 2 – please help us by sharing it with national medical advisers and all national doctors who you know are managing PID patients in your country:
In please find external helpful resources and updated information on the COVID-19 outbreak.
- The Plasma Protein Therapeutic Association (PPTA) has issued statements and information regarding the safety and supply of plasma derived medicinal products including immunoglobulins.
- The World Health Organisation (WHO) regularly publishes updates and new recommendations
WHO Newsroom // Detailed Q&As
- The European Centre for Disease Control (ECDC) regularly posts updates and offers a COVID-19 dedicated webpage
- The US CDC also offers resources and information
COVIBOOK – COVID 19 explained to children (in 17 languages)